PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy; VIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy.\', \'VIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy; Department of Medicine, Università degli Studi di Padova, Padova, Italy.\', \'Department of Medicine, Università degli Studi di Padova, Padova, Italy.\', \'Department of Medicine, Università degli Studi di Padova, Padova, Italy; Veneto Tumour Registry - Azienda Zero, Padova, Italy.\', \'Veneto Tumour Registry - Azienda Zero, Padova, Italy.\', \'Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland.\', \'Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.\', \'VIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy.\', \'Department of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy.\', \'Department of Oncological and Gastroenterological Sciences - Urology Unit, Azienda Ospedaliera di Padova, Padova, Italy.\', \'VIMM - Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy; Department of Medicine, Università degli Studi di Padova, Padova, Italy; Institute of Oncology Research, Oncology Institute of Southern Switzerland, Università della Svizzera Italiana, Bellinzona, Switzerland; Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland. Electronic address: andrea.alimonti@ior.iosi.ch.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0923-7534(20)39797-010.1016/j.annonc.2020.04.479
?:hasPublicationType
?:journal
  • Annals of oncology : official journal of the European Society for Medical Oncology
is ?:pmid of
?:pmid
?:pmid
  • 32387456
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32387456>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32387456>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all